Sepracor, Inc. engages in the research, discovery, development, and commercialization of pharmaceutical products for the treatment of respiratory and central nervous system disorders in the United States and Canada. It develops products for the synthesis and separation of pharmaceutical and biopharmaceutical compounds. The company markets XOPENEX (levalbuterol HCl) Inhalation Solution for the treatment of bronchospasm; XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane metered-dose inhaler for the treatment of bronchospasm; and LUNESTA (eszopiclone) for the treatment of insomnia. It also offers BROVANA (arformoterol tartrate) Inhalation Solution, a long-term...